Journal of Medicinal Chemistry · 2019 · 34 citations · 24 references
MedicineOncologyPharmacologyChemotherapyDrug DiscoveryStructure-activity RelationshipsCellular Drug EffluxCentral Nervous System Tumor PharmacotherapyEnzyme InhibitionLead Compound DesignOncology PharmacologyStructure-activity Relationship AnalysisAnticancer ActivityCarbonic Anhydrase InhibitorsChemotherapeutic EffluxGlioblastoma Therapeutic ResistanceOvercoming Multidrug ResistanceP-glycoprotein-mediated EffluxPrimary Brain NeoplasmsTemozolomide Therapy
The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor. We showed previously that the mechanism of action of 1 is novel, acting to indirectly interfere with P-glycoprotein drug efflux activity as a consequence of carbonic anhydrase XII (CA XII) inhibition. To build structure–activity relationships, 45 derivatives of 1 were designed, synthesized, and evaluated against a panel of CA isoforms. Compound 55 was identified as a potent inhibitor of CA XII (Ki = 0.56 nM) and was investigated in vitro and in vivo using samples from glioblastoma patients. The results strengthen the possibility that co-therapy of temozolomide with a CA XII inhibitor may more effectively treat glioblastoma by suppressing an important temozolomide resistance mechanism.
24
George A. Olah, Subhash C. Narang, B. G. B. GUPTA et al. · The Journal of Organic Chemistry · 1979 · 462 citations
Daniela Vullo, Alessio Innocenti, Isao Nishimori et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 215 citations · Full text
Jean‐Yves Winum, Daniela Vullo, Angela Casini et al. · Journal of Medicinal Chemistry · 2003 · 128 citations · Full text